About Our Current Research Studies
Our current studies and a brief description of each are listed below. More information about these studies, including eligibility criteria, funding sources, and team members involved can be found by clicking the study’s name.
Current Studies
A Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as an Adjunctive Treatment for Major Depressive Disorder (RELIGHT)
The Relight clinical research study is currently testing an investigational medication for people living with depression, or Major Depressive Disorder.
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NV-5138 in Adults with Treatment-Resistant Depression
This clinical research study helps evaluate the effectiveness and safety of an investigational medication used in conjunction with current antidepressant for symptoms of depression in people who have not responded well to treatment before.
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia
The TD-KINECTion Study is looking to see if taking valbenazine can improve the quality of life and overall health of people with tardive dyskinesia.
A Study of a Digital Therapeutic as Antipsychotic Therapy for Schizophrenia
A Multicenter, Randomized, Double-Blind, Parallel-Group, Controlled, 16-week Study to Evaluate the Efficacy and Safety of a Digital Therapeutic (CT-155) as an Adjunct to Standard-of-Care Antipsychotic Therapy in Adult and Late Adolescent Participants with Experiential Negative Symptoms of Schizophrenia
CONNEX 3 Study for Schizophrenia
A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of iclepertin once daily over 26 week treatment period in patients with schizophrenia
A study comparing TNX-1300 to placebo for treatment of cocaine intoxication
A single-blind, randomized study comparing the efficacy and safety of a single dose of TNX-1300 to placebo with usual care for the treatment of signs and symptoms of acute cocaine intoxication in emergency department subjects
